The role of probiotics in the treatment of gastrointestinal infections is increasingly being documented as an alternative or complement to antibiotics, with the potential to decrease the use of antibiotics or reduce their side effects. Although antibiotics-based Helicobacter pylori eradication treatment is 90% effective, it is expensive and causes antibiotic resistance associated with other adverse effects. Probiotics have an in vitro inhibitory effect on H. pylori. Animal studies demonstrated that probiotic treatment is effective in reducing H. pylori-associated gastric inflammation. About 12 human studies investigated the efficacy of combinations of antibiotics and probiotics, whereas 16 studies used probiotic alone as an alternative to antibiotics for the treatment of H. pylori infection. Most of the studies showed an improvement of H. pylori gastritis and decrease in H. pylori colonization after administration of probiotics. However, no study could demonstrate complete eradication of H. pylori infection by probiotic treatment. Probiotic combinations can reduce adverse effects induced by H. pylori eradication treatment and, thus, have beneficial effects in H. pylori-infected individuals. Long-term intakes of products containing probiotic strains may have a favorable effect on H. pylori infection in humans, particularly by reducing the risk of developing disorders associated with high degrees of gastric inflammation.
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Introduction
For a long time, ulcers were considered to be a result of stress and improper diet. The important discovery that ulcers are caused by a bacterial infection (Helicobacter pylori), which was rewarded with the 2005 Nobel Prize in Medicine, has changed gastroenterological practice worldwide. After its discovery, many gastroduodenal diseases became curable infectious diseases. H. pylori is a highly prevalent pathogen associated with chronic gastritis and peptic ulcer, and is a risk factor for gastric malignancies. The prevalence rate of H. pylori infection in the adult population of industrialized countries is estimated to be at 20e50% and in developing countries, the rate is as high as 80%. 1 H. pylori colonizes the stomach and induces chronic gastritis, a long-lasting inflammation of the stomach. The bacterium persists in the stomach for decades in many cases. However, most infected people may never experience clinical symptoms despite having chronic gastritis; 10e20% of those colonized by H. pylori may ultimately develop peptic ulcers.
2 H. pylori infection is also associated with 1e2% lifetime risk of stomach cancer and a less than 1% risk of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. This pathogen was designated as a class-I carcinogen for stomach cancer in 1994, after epidemiological investigation by the International Agency for Research on Cancer (IARC), a subordinate organization of the World Health Organization. 3 The infection is generally acquired during childhood and can persist indefinitely, if not treated systematically. 4 It has been suggested that H. pylori infection rates vary with age, ethnicity, socioeconomic status, sanitary environments, and lifestyle. 5 None of the antimicrobials is effective enough to eliminate H. pylori when given as a monotherapy; only a combination of these can wipe out H. pylori effectively. 4 According to Malfertheiner et al, 6 the first-line recommended eradication treatment of H. pylori consists of a combination of two antimicrobials and an acid-suppressive drug. This triple therapy used for the treatment of H. pylori has several adverse effects, such as diarrhea, nausea, bloating, and taste disturbance, possibly leading to discontinuation of the treatment, and limited efficacy principally because of antimicrobial resistance of the pathogen. 7 Alternative anti-H. pylori treatments are currently becoming more popular than the traditional eradication methods. Components that may be used either as a monotherapy or, synergistically, in combination with antimicrobials, resulting in a more effective anti-H. pylori therapy or an alternative way of controlling H. pylori infection, have been investigated in depth by several researchers. 2 It is believed that these novel therapies can potentially cut down the costs related to the treatment of H. pylori-associated diseases. One of the potential therapies involves an application of probiotic cultures; promising results have been observed in initial studies with numerous probiotic strains. Nevertheless, many questions remain unanswered. As defined by the Food and Agriculture Organization (FAO)/World Health Organization (WHO), 8 probiotics are live microorganisms that may confer a health benefit on the host. The most commonly used probiotic bacteria belong to the genera Lactobacillus and Bifidobacterium, and these also include several yeasts such as Saccharomyces boulardii. 9 In the current article, the possible mechanisms of action of probiotics on H. pylori infection, as reported by in vitro cell line and animal studies, are narrated, followed by the outcomes of the available in vivo evidences for the effect of probiotics on H. pylori infection in humans. The effect of the addition of probiotics to the standard H. pylori eradication therapy is also discussed.
Mechanisms of probiotic action on H. pylori
A number of mechanisms have been anticipated or hypothesized from in vitro studies of host intestinal epithelial or immune cell responses to probiotic strains. In that context, probiotic bacteria can inhibit H. pylori by either immunological or nonimmunological mechanisms. According to Haller et al, 10 distinct probiotic strains may generate divergent immune responses depending on the host's immune status.
Animal studies suggested that the immunomodulatory effects of probiotic bacteria may be mediated through immune regulation, particularly through controlling the balance of proinflammatory and anti-inflammatory cytokines and chemokines, which in turn would reduce gastric activity and inflammation. 11 Probiotic bacteria can bind to recognition receptors, such as Toll like receptors (TLRs) expressed on the surface of epithelial cells, and thus trigger a cascade of immunological defense mechanisms. 9 In that TLR4 can recognize lipopolysaccharide of Gram-negative bacteria, whereas TLR2 can recognize a variety of microbial components, such as peptidoglycan and teichoic acids, present in Gram-positive bacteria. 12 The cytokine response is initially manifested by the release of interleukin (IL)-8, which leads to the migration of neutrophils and monocytes to the mucosa. 13 These activated monocytes and dendritic cells stimulate production of various cytokines together with IL-4, IL-5, IL-6, and interferon-g. According to Gill, 14 probiotics can modify the immunologic response of the host by interacting with epithelial cells and modulating the secretion of anti-inflammatory cytokines, resulting in a reduction of gastric activity and inflammation. In one of the earlier studies, Kabir et al 15 demonstrated that Lactobacillus salivarius inhibits H. pylori-stimulated secretion of IL-8 by gastric epithelial cells. During several animal studies, a decrease in specific IgG antibodies to H. pylori infection, parallel to a fall in gastric inflammation, was observed following a probiotic intake. 16, 17 Also, enhancement of secretory IgA production in the intestinal epithelium may have a role in pathogen defense through strengthening of the mucosal barrier. 13, 18 It was also established that H. pylori infection induces production of Smad7, nuclear factor (NF)-kB, IL-8, and tumor necrosis factor-a in vitro. In a recent investigation, Yang et al 19 observed that pretreatment of Lactobacillus acidophilus at higher doses reduced H. pylori-induced inflammation through the inhibition of H. pylori-induced Smad7 transcription, by inactivating the Jak1 and Stat1 pathways, and subsequently reduced nuclear NF-kB production.
Nonimmunological mechanisms of probiotics include strengthening of mucosal barrier by producing antimicrobial substances, coaggregation with pathogens, competing with H. pylori for adhesion receptors, stimulating mucin production, and stabilization of the gut mucosal barrier. Generally, probiotics such as lactic acid bacteria (LAB) and bifidobacteria are able to produce organic acids, hydrogen peroxide, carbon dioxide, and some other antimicrobial compounds to inhibit potential pathogens. 20 Adhesion of pathogens can also be inhibited by steric hindrance, where a large number of beneficial bacteria may cover receptor sites in a non-specific manner, or by competing for specific carbohydrate receptors that would otherwise be available to pathogens. Several probiotic species have shown growth inhibition or antiadhesion ability against H. pylori in a gastric epithelial cell model. 16, 21 Mucins, secreted by epithelial cells, may also bind to pathogens, thereby inhibiting their adherence to epithelial cells. Probiotics can interfere with the actions of H. pylori, since several strains such as Lactobacillus plantarum 299V and Lactobacillus rhamnosus GG have been shown to induce mucin gene expression. 22, 23 Furthermore, some Bifidobacterium strains have been found to release heat-stable proteinaceous antimicrobial compounds against H. pylori in vitro.
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Probiotics and H. pylori infection
In the majority of studies dealing with either animal models or humans, the most frequently used strains were Lactobacillus johnsonii La1 and L. rhamnosus GG, either in a fermented milk preparation containing live bacteria 25e27 or as a cell-free culture supernatant, 28 followed by other probiotics such as Lactobacillus casei, L. acidophilus, Lactobacillus brevis and Lactobacillus gasseri OLL2716, Lactobacillus reuteri, Bifidobacterium. lactis, Bifidobacterium animalis, Bifidobacterium breve, Propionibacterium freudenreichii and probiotic yeast S. boulardii. The effect of probiotics on H. pylori gastritis is commonly measured by the rapid urease tests, urea breath test (UBT), serological assays, stool antigen test, and histological examination of gastric biopsies. 2,3,17,25e27 The outcomes of various in vitro and in vivo clinical studies are discussed in the following sections. They have been categorized as studies in experimental animals and cell lines; and human studies, for better understanding the effect of individual probiotic strain or combination of thereof on H. pyroli infection.
Clinical studies using experimental animals and cell lines
Various probiotics have shown favorable effects in animal models of H. pylori infection (Table 1) . In a few preliminary studies, oral administrations of L. salivarius to H. pyloriinfected gnotobiotic BALB/c mice showed a highly protective and therapeutic effect. 15, 17 Similarly, Coconnier et al 29 reported that L. acidophilus strain LB was able to protect against H. pylori infection in conventional mice. In a C57BL/6 mice model of infection, a probiotic combination containing L. acidophilus R0052 and L. rhamnosus R0011 was found to reduce the effects of H. pylori infection 4 Z no effect.
through reducing H. pylori colonization and alleviating H. pylori-induced inflammation of the stomach. 31 In a Mongolian gerbil model of H. pylori infection, the same probiotic preparation was proved effective via its attenuating effect on H. pylori colonization, mucosal inflammation, and impairment of the gastrinesomatostatin link. 33 Studies by Sgouras and coworkers 16, 32 in a C57BL/6 mice model demonstrated that L. casei strain Shirota and L. johnsonii La1, both administered in drinking water, attenuated H. pylori infection-induced gastric mucosa inflammation. However, only L. casei strain Shirota was able to downregulate the colonization of H. pylori to gastric mucosa. In another study, L. gasseri was found to decrease colonization of clarithromycin-resistant H. pylori.
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The potential of recombinant Lactobacillus or any other probiotics to be used as antigen-delivery vehicles to induce protective immune responses has rarely been studied. A recombinant L. plantarum strain producing H. pylori urease B subunit was found to induce successfully a partial mucosal protection against the pathogenic strain. 34 By contrast, in the study carried out by Lee et al, 35 Lactococcus lactis-producing cytoplasmic urease B was shown to be unable to induce protection against H. pylori in a mouse model.
Recently, Chen et al 36 assessed the antagonistic activities of Lactobacillus strains against H. pylori growth in a co-culture system and its infection in human gastric epithelial cells. Results showed that the Lactobacillus strains had significant anti-H. pylori activity, which can be attributed to the cell-free supernatants of lactobacilli and live Lactobacillus strains in vitro.
Clinical studies on humans
Numerous clinical trials in humans for the treatment of H. pylori infection have been documented (Table 2) . 25,37e47 The role of probiotics in the treatment of H. pylori infection is acknowledged either as a complement or as an alternative to antibiotics, having the potential to decrease the use of antibiotics. However, occurrence of side effects is one of the major drawbacks of antibiotic treatment. Gastrointestinal manifestations may be related to alterations in the intestinal microflora. Probiotics can prevent or reduce antibiotic-associated side effects and have an inhibitory effect on H. pylori. In 2000, the first study on humans was conducted by Canducci and coworkers, 37 which provided evidence that L. acidophilus LB improved the rate of H. pylori eradication significantly in the probiotic group. However, the supplementation did not alleviate the side effects of the antiHelicobacter treatment. In that connection, two separate double-blind studies reported that L. rhamnosus GG was able to reduce the occurrence of adverse effects including diarrhea, nausea, and bloating, unlike the outcomes of the previous study. 38, 39 Based on the results of an open and uncontrolled clinical trial, Sheu et al 40 reported that a yoghurt containing L. acidophilus La5 and B. lactis Bb12 was able to increase the eradication rate and also decrease some side effects of the triple therapy. In another study, Cremonini et al 41 observed that the administration of L. rhamnosus GG, probiotic yeast S. boulardii, or a combination of L. acidophilus and B. lactis for 2 weeks also decreased adverse events during the triple treatment. The effects of a probiotic supplementation seemed to be independent of the probiotic species used. In a 10-day quadruple anti-Helicobacter therapy with L. casei ssp. casei DG, the supplementation improved significantly the eradication rate in patients after failure of the first-line eradication treatment. 42 Similarly, in patients with H. pylori resistance, L. acidophilus La5 combined with B. lactis Bb12 improved the second-line rescue therapy. 45 Myllyluoma et al, 25 in a randomized double-blind study, used a combination of several probiotics and observed a decrease in gastritis and H. pylori colonization in 118 individuals.
To date, only two studies have been conducted in dyspeptic children. In the earliest study, fermented milk products containing L. casei DN-114 001 were found to increase the eradication rate of standard triple treatment efficiently. 43 The second study was carried out by Lionetti et al, 44 where L. reuteri was found to alleviate eradication treatment, with associated adverse effects. In a recent study of Ojetti et al 47 conducted in H. pylori-positive patients, L. reuteri supplementation increased the eradication rate, at the same time decreasing the incidence of the most common side effects associated with antibiotic therapy in the second-line treatment.
Studies concerning the attenuation of microbiota disturbances with probiotics following an anti-Helicobacter triple treatment are limited. Madden and coworkers 48 found that a probiotic combination, which included two strains of L. acidophilus (CLT60 and CUL21) and two strains of B. bifidum (CUL17 and B. bifidum Rhodia), stabilized the number of facultative anaerobes. Later, Plummer et al 49 reported that the same probiotic preparation was able to diminish the amount of antibiotic resistance among enterococci and reduce disruption of the enterobacterial component in the regrowth population.
Probiotics as an alternative to antimicrobials have also been the focus of several studies (Table 3) . 27,28,50e63 Initially, Mrda and coworkers 50 studied the effect of acidophilus milk containing live probiotic bacteria on 14 individuals and observed a decrease in H. pylori colonization, with a simultaneous increase in the eradication rate. Administration of a culture supernatant or fermented milk containing the strain of L. acidophilus La1 was found to decrease H. pylori urease activity, as measured by 13 C-UBT values in adults 28 and children 54 ; similar results were observed in two other trials, as confirmed by histological analysis. 2, 55 In the latter two studies, a decrease in H. pylori infection-associated inflammation was evident. However, none of the studies reported that regular intake of L. acidophilus (johnsonii) La1 eradicated H. pylori. In a study conducted by Sakamoto et al 51 in 31 patients with H. pylori infection, it was indicated that L. gasseri OLL2716 was effective in suppressing H. pylori and reducing gastric mucosal inflammation, as measured by 13 C-UBT values and assays of serum pepsinogen I. Similar results were obtained by Shimizu et al, 53 using L. gasseri OLL2716 in 12 children. In another study, L. casei was also shown to inhibit H. pylori growth, as reflected by a reduction in 13 C-UBT values. 56 Similar effects on the growth of H. pylori were reported by Wang et al 58 in a study of 59 human volunteers who consumed yoghurt containing L. acidophilus La5 and 
Milk-based drink, 1 Â 10 9 CFU/mL, twice a day for 4 wk followed by once a day for 6 wk [ Z increase; Y Z decrease; 4 Z no effect. 26 The eradication rate was slightly better in the study group using S. boulardii combined with inulin. In another study, Gotteland et al 59 recorded similar results with L. johnsonii La1, in 295 asymptomatic children, using a mixture of cranberry juice (200 mL) and La1 product (80 mL) as a synbiotic preparation.
Safety aspects
Even though LAB have been granted generally recognized as safe (GRAS) status by the WHO, each probiotic strain requires a safety assessment. Different strains of probiotics have different safety profiles, which should be taken into account, and generalizations concerning all probiotics should be avoided. 60 Lactobacilli and bifidobacteria are part of normal gastrointestinal microbiota, and systemic infections with these bacteria may thus occur naturally, unrelated to the ingestion of probiotics. Data on the safety of probiotics suggest that probiotic therapy is generally considered safe. 60, 64 A lethal dose (LD 50 ) of LAB, as measured for mice when administered orally, was found to be >10 11 CFU/kg, depending on the strain. 65 Bifidobacteria have been found to be even safer because no cases of sepsis related to probiotic ingestions have been reported. The safety of two Bifidobacterium longum strains of human origin was evaluated in healthy adult volunteers; no side effects were reported and even the immune parameters measured remained stable, without any undesirable changes. 66 Propionibacteria are also regarded as safe, mainly because of their long history of safe use in Emmental cheese manufacturing. Propionibacterium freudenreichii ssp. shermanii has consequently been proposed to be granted "Qualified Presumption of Safety" status by the European Food Safety Authority. 67 Safety considerations regarding antimicrobial resistance are also taken into account while using probiotics. There are questions about the possibility of resistance transfer both from probiotics to pathogenic bacteria and from commensal microbiota to probiotics. Probiotic strains are generally susceptible to the majority of antibiotics, although several studies have indicated that they can survive gastrointestinal transit reasonably well during antibiotic treatment. 68 However, this did not lead to the transfer of resistance genes from original microbiota to the ingested probiotics.
In conclusion, the majority of the compiled studies propose that consumption of certain strains of probiotics may be useful in combating H. pylori infection as a complement to the first-or second-line eradication therapy. These probiotic strains are able to improve patient compliance by reducing antibiotic-associated adverse events, increasing the number of patients completing the eradication therapy and resulting in an improved eradication rate. Complete eradication of H. pylori without an anti-Helicobacter therapy has not succeeded; however, regular consumption of probiotic products with specific strains as an alternative to antibiotics may have some potential in the suppression of H. pylori infection. In order to further evaluate the potential efficacy of this probiotic combination against H. pylori infection, studies comprising a larger number of patients are necessary. It should be possible to eradicate H. pylori infection with optimal efficacy and tolerability to avoid excess use of antibiotics and to offer alternative ways of controlling H. pylori infection if eradication treatment is not recommended.
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